Mental health-related drug utilization among older adults: Prevalence, trends, and costs

American Journal of Geriatric Psychiatry

Volumn 13, Issue 10, 2005, Pages 892-900

  Mamdani, Muhammad ^a,c,d   Rapoport, Mark ^b,d   Shulman, Kenneth I ^b,d   Herrmann, Nathan ^b,d   Rochon, Paula A ^a,d,e  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG USE; DRUG UTILIZATION; ELDERLY CARE; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH; PRESCRIPTION; PREVALENCE; CANADA; COST; CROSS-SECTIONAL STUDY; ECONOMICS; HEALTH SURVEY; MENTAL DISEASE; MIDDLE AGED; STATISTICS;

AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; HUMANS; MENTAL DISORDERS; MIDDLE AGED; ONTARIO; POPULATION SURVEILLANCE; PREVALENCE;

EID: 33644875033     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/00019442-200510000-00009     Document Type: Article

References (22)

1. Shulman KI, Rochon P, Sykora K, et al: Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ 2003; 326(7396):960-961
2. Martin BC, Miller LS, Kotzan JA: Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five-year time-series forecasts. Schizophr Res 2001; 47:281-292
3. Mamdani MM, Parikh SV, Austin PC, et al: Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 2000; 157:360-367
4. Mittmann N, Herrmann N, Einarson TR, et al: The efficacy, safety, and tolerability of antidepressants in late-life depression: a meta-analysis. J Affect Disord 1997; 46:191-217
5. Herrmann N, Lanctot KL: From transmitters to treatment: the pharmacotherapy of behavioural disturbances in dementia. Can J Psychiatry 1997; 42(suppl1):51S-64S
6. Shulman KI, Herrmann N: The nature and management of mania in old age. Psychiatr Clin North Am 1999; 22:649-665, ix
7. Hanlon JT, Horner RD, Schmader KE, et al: Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 1998; 64:684-692
8. Ray WA, Thapa PB, Gideon P: Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 2000; 48:682-685
9. Hemmelgarn B, Suissa S, Huang A, et al: Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278:27-31
10. Grad RM: Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. J Fam Pract 1995; 41:473-481
11. Petrovic M, Mariman A, Warie H, et al: Is there a rationale for prescription of benzodiazepines in the elderly? review of the literature. Acta Clin Belg 2003; 58:27-36
12. Doody RS, Stevens JC, Beck C, et al: Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1154-1166
13. Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias of Late Life: American Psychiatric Association. Am J Psychiatry 1997; 154(suppl5):1-39
14. Patterson CJ, Gauthier S, Bergman H, et al: The recognition, assessment, and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ 1999; 160(suppl12):S1-15
15. Courtney C, Farrell D, Gray R, et al: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised, double-blind trial. Lancet 2004; 363(9427):2105-2115
16. Levy AR, O'Brien BJ, Sellors C, et al: Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003; 10:67-71
17. Pindyck RS, Rubinfeld DL: Econometric Models and Economic Forecasts. New York, McGraw-Hill, 1998
18. Kramer M, German PS, Anthony JC, et al: Patterns of mental disorders among the elderly residents of eastern Baltimore. J Am Geriatr Soc 1985; 33:236-245
19. Garrard J, Rolnick SJ, Nitz NM, et al: Clinical detection of depression among community-based elderly people with self-reported symptoms of depression. J Gerontol A Biol Sci Med Sci 1998; 53:M92-M101
20. Callahan CM, Hendrie HC, Tierney WM: Documentation and evaluation of cognitive impairment in elderly primary-care patients. Ann Intern Med 1995; 122:422-429
21. Whittington CJ, Kendall T, Fonagy P, et al: Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363(9418):1341-1345
22. McShane R, Keene J, Gedling K, et al: Do neuroleptic drugs hasten cognitive decline in dementia? prospective study with necropsy follow up. BMJ 1997; 314(7076):266-270